eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

vol. 11
Review paper

Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review

Luca Tagliaferri, Monica Maria Pagliara, Bruno Fionda, Andrea Scupola, Luigi Azario, Maria Grazia Sammarco, Rosa Autorino, Valentina Lancellotta, Silvia Cammelli, Carmela Grazia Caputo, Rafael Martìnez Monge, György Kovács, Maria Antonietta Gambacorta, Vincenzo Valentini, Maria Antonietta Blasi

J Contemp Brachytherapy 2019; 11, 1: 54–60
Online publish date: 2019/02/13
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
To report the results of a patient’s tailored therapeutic approach using a second course of interventional radiotherapy (brachytherapy) in patients with locally recurrent uveal melanoma.

Material and methods
Patients who had already undergone ocular brachytherapy treated at our IOC (Interventional Oncology Center) were considered. Five patients who has received a second course of treatment with a plaque after local recurrences were included in our study. Re-irradiation was performed with Ruthenium-106 (prescribed dose to the apex 100 Gy) or with Iodine-125 plaques (prescribed dose to the apex 85 Gy). Moreover, a systematic literature search was conducted through three electronic databases, including Medline/PubMed, Scopus, and Embase.

All patients were initially treated with Ruthenium-106 plaque; the re-irradiation was performed with Ruthenium-106 plaque in three cases and with Iodine in two cases. Mean time between the first and the second plaque was 56.8 months (range, 25-93 months). Local tumor control rate was 100%, no patient underwent secondary enucleation owing to re-treatment failure. Distant metastasis occurred in 1 patient after 6 months from re-treatment. After a median follow-up of 44.2 months (range, 26-65 months) from re-treatment, all patients experienced worsening of the visual acuity (median visual acuity was 0.42 at time of recurrence and decline to 0.24 at the most recent follow-up); cataract occurred in two cases, no patient developed scleral necrosis. We considered 2 papers for a systematic review.

In selected cases, especially in presence of marginal local recurrence, a personalized re-treatment strategy with a plaque may offer high probability of tumor control and organ preservation but worsening of visual acuity.


uveal melanoma, brachytherapy, re-treatment, re-irradiation

Rao YJ, Sein J, Badiyan S et al. Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis. J Contemp Brachytherapy 2017; 9: 453-465.
Shields CL, Shields JA, Karlsson U et al. Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings. Ophthalmology 1989; 96: 919-923.
Chang MY, McCannel TA. Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmol 2013; 97: 804-811.
Desjardins L. Choroidal melanoma. Rev Infirm 2016; 219: 23-24.
Caujolle JP, Paoli V, Chamorey E et al. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences. Int J Radiat Oncol Biol Phys 2013; 85: 1218-1224.
Melia M, Moy CS, Reynolds SM et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. Arch Ophthalmol 2006; 124: 226-238.
Miguel D, De Frutos-Baraja JM, López-Lara F et al. Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses. J Contemp Brachytherapy 2018; 10: 123-131.
Tagliaferri L, Kovács G, Autorino R et al. ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy). J Contemp Brachytherapy 2016; 8: 336-343.
Kovács G, Tagliaferri L, Valentini V. Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemp Brachytherapy 2017; 9: 497-498.
Tagliaferri L, Pagliara MM, Boldrini L et al. INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures. J Contemp Brachytherapy 2017; 9: 287-295.
Valentini V, Maurizi F, Tagliaferri L et al. Spider: managing clinical data of cancer patients treated through a multidisciplinary approach by a palm based system. Italian Journal of Public Health 2012; 5: 154-164.
Tagliaferri L, Pagliara MM, Masciocchi C et al. Nomogram for predicting radiation maculopathy in patients treated with Ruthenium106 plaque brachytherapy for uveal melanoma. J Contemp Brachytherapy 2017; 9: 540-547.
Tagliaferri L, Bussu F, Fionda B et al. Perioperative HDR brachytherapy for reirradiation in head and neck recurrences: single-institution experience and systematic review. Tumori 2017; 103: 516-524.
Strnad V, Pötter R, Kovács G et al. Practical handbook of brachytherapy. Bremen UNI-MED Verl. 2014.
Seibel I, Cordini D, Rehak M et al. Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches, and outcome. Am J Ophthalmol 2015; 160: 628-636.
Miguel D, De Frutos-Baraja JM, López-Lara F et al. Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after episcleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I. J Contemp Brachytherapy 2018; 10: 337-346.
Miguel D, De Frutos-Baraja JM, López-Lara F et al. Radiobiological doses, tumor, and treatment features influence on outcomes after episcleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II. J Contemp Brachytherapy 2018; 10: 347-359.
Kowal J, Markiewicz A, Dębicka-Kumela M et al. Outcomes of I-125 brachytherapy for uveal melanomas depending on irradiation dose applied to the tumor apex – a single institution study. J Contemp Brachytherapy 2018; 10: 532-541.
Rospond-Kubiak I, Wróblewska-Zierhoffer M, Twardosz-Pawlik H et al. Ruthenium brachytherapy for uveal melanoma – single institution experience. J Contemp Brachytherapy 2017; 9: 548-552.
Naseripour M, Jaberi R, Sedaghat A et al. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachytherapy 2016; 8: 66-73.
Gagne NL, Cutright DR, Rivard MJ. Keeping an eye on the ring: COMS plaque loading optimization for improved dose conformity and homogeneity. J Contemp Brachytherapy 2012; 4: 165-175.
Chang MY, McCannel TA. Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmol 2013; 97: 804-811.
Almony A, Breit S, Zhao H et al. Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma. Arch Ophthalmol 2008; 126: 65-70.
Harbour JW, Murray TG, Byrne SF et al. Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. Retina 1996; 16: 129-134.
Finger PT, Romero JM, Rosen RB et al. Three-dimensional ultrasonography of choroidal melanoma: localization of radioactive eye plaques. Arch Ophthalmol 1998; 116: 305-312.
Desjardins L, Lumbroso L, Levy C et al. Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates. J Fr Ophtalmol 2003; 26: 269-276.
Marucci L, Lane AM, Li W et al. Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma. Int J Radiat Oncol Biol Phys 2006; 64: 1018-1022.
Gaspar de Souza Neves DF, Ferragut MA, Ferreira DV et al. Reirradiation of the eye with plaque brachytherapy: a single institution experience report of eight consecutive patients submitted to retreatment after local relapse of malignant disease of the eye. Brachytherapy 2014; 13: 281-284.
King B, Morales-Tirado VM, Wynn HG et al. Repeat episcleral plaque brachytherapy: clinical outcomes in patients treated for locally recurrent posterior uveal melanoma. Am J Ophthalmol 2017; 176: 40-45.
Pagliara MM, Tagliaferri L, Azario L et al. Ruthenium Interventional Radiotherapy (brachytherapy) for uveal melanoma: an analysis of factors favoring the development of radiation complications. Brachytherapy 2018; 17: 432-438.
Damiani A, Masciocchi C, Boldrini L et al. Preliminary data analysis in healthcare multicentric data mining: a privacy-preserving distributed approach. JE-LKS. Journal of E-learning and Knowledge Society 2018; 14. ISSN: 1826-6223.
Meldolesi E, Van Soest J, Alitto AR et al. VATE: VAlidation of high TEchnology based on large database analysis by learning machine. Future Medicine 2014; 3: 435-450.
Tagliaferri L, Gobitti C, Colloca GF et al. A new standardized data collection system for interdisciplinary thyroid cancer management: Thyroid COBRA. Eur J Intern Med 2018; 53: 73-78.
Tagliaferri L, Budrukkar A, Lenkowicz J et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). J Contemp Brachytherapy 2018; 10: 260-266.
Blasi MA, Laguardia M, Tagliaferri L et al. Brachytherapy alone or with neoadjuvant photodynamic therapy for amelanotic choroidal melanoma: functional outcomes and local tumor control. Retina 2016; 36: 2205-2212.
Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye (Lond) 2013; 27: 163-171.
Chaudhry IA, Liu M, Shamsi FA et al. Corneoscleral necrosis after episcleral Au-198 brachytherapy of uveal melanoma. Retina 2009; 29: 73-79.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe